GLP1R and hematopoietic and lymphoid system neoplasm: To understand how the use of GLP-1 receptor agonists impacts the risk of hematologic neoplasms, we utilized the TriNetX database, which contains coded diagnostic, treatment, and laboratory data for 129 million individuals.